Literature DB >> 380947

Management of the perineal wound after rectal excision for neoplastic disease: a controlled clinical trial.

O Terranova, F Sandei, C Rebuffat, R Maruotti, G Pezzuoli.   

Abstract

Two methods of management of the perineal wound after rectal excision for neoplastic disease were compared in a prospective randomized clinical trial in 65 patients. Twenty-eight patients (Group A) were treated by partial closure of the perineal wound and cigarette drainage of the pelvic space, according to the method proposed by Gabriel. Thirty-seven patients (Group B) were treated by complete suture of the perineal wound and suction drainage of the pelvic space according to the method proposed by Altemeier. Immediate and late results were better in patients in Group B. They achieved healing per primam in 62.82 per cent of cases and had significantly shorter hospital stays than patients in Group A. Three months postoperatively, 91.42 per cent of patients in Group B and 59.25 per cent of those in Group A had complete healing of the perineal wounds, with a statistically significant difference (chi2 with Yates correction = 7.27, P less than 0.01). The development in 10 patients of Group B of perineal abscesses or hematomas necessitated reopening of the perineal wounds: however, the postoperative courses were similar to those of patients in Group A. It is concluded that healing by primary intention with use of the method described herein is the treatment of choice for managing the perineal wounds in patients undergoing rectal excision for neoplastic disease.

Entities:  

Mesh:

Year:  1979        PMID: 380947     DOI: 10.1007/bf02586880

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  1 in total

Review 1.  Local Application of Gentamicin in the Prophylaxis of Perineal Wound Infection After Abdominoperineal Resection: A Systematic Review.

Authors:  G D Musters; J W A Burger; C J Buskens; W A Bemelman; P J Tanis
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.